EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Cartesian Therapeutics, Inc. (RNAC) had EBITDA Margin of -5021.31% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.80M |
|
$-130.30M |
|
-- |
|
$2.80M |
|
$146.20M |
|
$-143.41M |
|
$3.91M |
|
$-139.50M |
|
$-139.50M |
|
$-130.30M |
|
$-130.30M |
|
$-130.30M |
|
$-130.30M |
|
$-143.41M |
|
$-140.45M |
|
25.97M |
|
25.97M |
|
$-5.02 |
|
$-5.02 |
|
| Balance Sheet Financials | |
$129.28M |
|
$12.19M |
|
$167.13M |
|
$296.41M |
|
$14.94M |
|
-- |
|
$407.71M |
|
$422.65M |
|
$-126.24M |
|
$-174.40M |
|
$-126.24M |
|
26.01M |
|
| Cash Flow Statement Financials | |
$-73.94M |
|
$-5.45M |
|
$-8.05M |
|
$214.28M |
|
$126.87M |
|
$-87.41M |
|
$10.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-5127.10% |
|
-5127.10% |
|
|
EBITDA Margin |
-5021.31% |
-4987.31% |
|
-4658.64% |
|
$-79.39M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
2.51 |
|
145.50 |
|
103.22% |
|
74.71% |
|
-43.96% |
|
103.22% |
|
$-4.85 |
|
$-3.06 |
|
$-2.85 |
|